INTRODUCTION
Solid organ transplantation is the standard of care for patients with advanced organ disease and certain cancers. However, the need for donated organs substantially exceeds the supply. By the end of 2014, nearly 130 000 patients were waitlisted in the United States whereas fewer than 30 000 received transplants. Each year 10-15% of candidates die on the waitlist, which has increasingly led to the use of living organ donors. In order to optimize outcomes in this situation of scarce resources, candidates must be carefully selected for transplantation.
Improvements in preoperative management [e.g., mechanical circulatory support (MCS) for heart transplant candidates)], surgical innovations (e.g., the use of laparoscopic surgery for kidney transplant) and the development of less toxic immunosuppressive medications have resulted in reduced long-term morbidity and mortality for transplant recipients. However, increasing evidence suggests that psychiatric and behavioral factors affect pretransplant selection and long-term posttransplant outcomes. The critical need for transplant recipients to adopt lifelong self-care management behaviors has led to the development of psychotherapeutic and behavioral interventions for improving sustained adherence to all facets of the posttransplant regimen.
Psychiatrists and other mental health professionals typically assist with evaluating and
MOOD AND PSYCHOTIC DISORDERS
Rational selection of transplant candidates maximizes benefit to patients and society and ensures public trust in the process of organ allocation, an important facet of which is the consideration of equity for disadvantaged patients. However, there is neither a standard psychosocial evaluation process nor selection criteria across transplant centers and different criteria may be considered relevant depending on the transplanted organ. Each transplant programme must decide on specific psychosocial criteria and the relevance of these criteria for individual patients, often with input from mental health professionals. Concerns still exist that patients with preexisting serious mental illness (SMI; including schizophrenia and other psychotic disorders, bipolar disorder, major depressive disorder, and severe posttraumatic stress disorder) may be less likely to be adherent to posttransplant care. Some guidelines consider a preexisting psychotic disorder as a relative contraindication to transplantation [1] .
In response to these concerns, Evans et al. [2 && ] analyzed health services data for 822 solid organ transplants in the national Veteran Administration system and found that 17% of transplant recipients suffered from SMI, whereas 30% carried other mental health diagnoses. The study found no difference in attendance at follow-up appointments, frequency of filling immunosuppressant prescriptions, or 3-year mortality among those with SMI, another mental health diagnosis, or no mental health diagnosis. Similarly, Price et al. [1] , in a recent review, found no evidence of poorer posttransplant adherence in patients with psychotic disorders than in patients without. Recent publications indicate a consensus opinion that psychiatric disorders must be well controlled before transplantation and that psychosocial supports must be optimized to help patients cope with the stresses of transplantation and remain adherent to follow-up care [3, 4] Although there is little evidence that SMIs impact adherence in organ transplants, recent studies continue to demonstrate a negative effect of clinically significant depression and depressive symptoms (measured with standard rating scales) on transplant outcomes when assessed both before [5] and following transplantation [5, 6] . In one of the few studies that examined depression and anxiety disorders prospectively using a Diagnostic and Statistical Manual of Mental Disorders-IV-R (DSM-IV-R) structured interview in a cohort of lung transplant recipients, posttransplant depression predicted not only poorer patient and graft survival but also the development of bronchiolitis obliterans syndrome [7] . Anxiety was not significantly associated with these poorer outcomes. A recent meta-analysis of the literature indicates that depression, either pretransplant or posttransplant, has a strong negative impact on posttransplant survival [8] . Morbidities are infrequently studied but appear also to be predicted by the presence of depression. The small amount of literature on anxiety's impact on outcomes is mixed, although many studies indicate that anxiety is not related to outcomes. Some studies suggest that treating psychiatric disorders could lessen the impact of depression [9] , but further research is needed.
SUBSTANCE USE AND DISORDERS
Substance use is a common concern for transplant programmes specifically due to the negative affect of substances on health and organ function. This is of particular concern in patients who have received transplanted organs, as substance use and the accompanying psychosocial problems place patients and transplanted organs at risk from direct toxicity of the substance, increased risk of infection due to risky behaviors, and increased incidence of nonadherence to immunosuppressants leading to organ rejection [10] . In general, a 6-month period of abstinence from use of substances is required before transplantation although not all substances are
KEY POINTS
Patients with complex substance and mental health disorders can achieve good posttransplant outcomes with expert management perhaps optimally delivered through mental health provider/teams embedded within the transplant service to provide collaborative longitudinal care.
Psychiatric distress and disorders should be screened for and treated to improve quality of life and wellbeing if not potentially reducing the risk for poorer survival and increased morbidity posttransplant.
In addition to interventions that target a specific facet of behavior, such as medication taking, adherence interventions that are individually tailored to the specific and possibly multiple needs of transplant recipients are required. These may be especially necessary for complex patients who may require more intensive strategies.
considered equally across different types of organ transplant programmes with regard to this requirement. For example, although there is general consensus regarding the need for abstinence from alcohol use among individuals with histories of abuse, no matter what the type of transplant programme, heart and lung transplant programmes also require abstinence from tobacco use whereas abdominal transplant programmes may not impose this requirement.
Cannabis use has grown with the advent of medical prescribing and legalization in certain states. As yet, there is no consensus across transplant centers as to how this will affect selection criteria. Although some transplant programmes exclude patients who are actively using marijuana [11] , this remains controversial. A prior Current Opinions review suggested that potential cannabis effects (e.g., increased infection risk, cancer, and psychological effects) may negatively impact transplant outcomes [12] , but no studies have examined this since then. Beyond recreational cannabis use, psychiatrists should evaluate for substance use disorders, educate patients about the medical and psychological outcomes of substance abuse, and provide assistance toward addiction treatment.
Rodrigue et al. [13] compared liver transplant patients who received substance abuse counseling at various points in the transplant process and found that those who received treatment before and after transplant had significantly lower relapse rates than those who received no treatment or treatment only pretransplant (16% versus 41% or 45%, respectively). Risk factors for relapse into problem drinking include: shorter pretransplant abstinence, more attempts to quit drinking, history of treatment for psychological problems, noncompliance with medical follow-up posttransplant, smoking posttransplant, and a first-degree relative with alcohol abuse [14, 15] . Positive relationships in the patient's life were negatively correlated with relapse [16] . A pretransplant screening tool has been developed to predict relapse into any amount of alcohol use after transplantation [17] .
A recent controversial study from Europe demonstrating successful outcomes for carefully selected patients with acute alcoholic hepatitis (AAH) [18] , has created discussion about transplanting patients with very short abstinence. AAH occurs in the context of active drinking and typically has a rapidly deteriorating course that would not allow six months of abstinence to be achieved. Some transplant programmes are beginning to consider, evaluate, and even transplant such patients. Psychiatrists should be prepared to evaluate and provide treatment recommendations for short abstinence patients, keeping in mind that limited time and potential encephalopathy and/or physical debility could impede engagement in treatment. Weinrieb et al. [19] determined that liver transplant candidates often do not perceive a need for addiction counseling and that motivational interviewing techniques may be helpful to facilitate addiction treatment engagement. For those too ill to complete rehabilitation before liver transplantion, contracting for ongoing addiction counseling following transplantation may be considered. One study examined the impact of embedding an alcohol addiction treatment unit (AAU) within the liver transplant team. This unit focused on the assessment, selection, and monitoring of candidates with alcohol use disorders providing collaborative care before and after liver transplant [20 && ]. Liver transplant recipients managed by the AAU appeared to have less after liver transplant alcohol recidivism (16.4 versus 35.1%) and improved survival [20 && ], but recidivism results were not adjusted for time since liver transplant. Within the AAU-treated group, there was no difference in relapse based on more or less than 6 months pretransplant abstinence, suggesting that transplanting patients with less than 6 months abstinence might be considered in selected patients managed by an AAU. Ongoing monitoring even on the liver transplant waitlist is needed, as up to 25% of waitlisted alcoholic patients may drink [19] ; measuring random blood alcohol levels may be potentially effective for identifying the majority of those who are drinking [21] .
COGNITIVE IMPAIRMENT
Assessing cognitive function in transplant candidates is essential to identifying deficits that could compromise patients' capacity to comprehend and participate in decision-making before surgery and, if permanent, to understand and adhere to posttransplant treatment directives. Caregivers are also affected by patients' cognitive deficits, as the burden of assisting with following medical directives or even basic activities of daily living could become their responsibility. Psychiatrists can play an important role in identifying cognitive impairment as assessment of cognition is part of a complete psychiatric evaluation. Whereas serial cognitive assessment is recommended for evaluating the effects of disease progression over time, prospective studies with this design are infrequently undertaken.
In heart transplantation, the increasing use of MCS as a bridge to transplant may reduce cognitive impairment from low cardiac output whereas simultaneously introducing adverse neurological and psychiatric events. More recently, nonpulsatile flow MCS devices have demonstrated significant improvements in reducing morbidity and mortality and are half as likely as the older, pulsatile flow devices to be associated with neurological dysfunction and psychiatric episodes [22] . A prospective study of cognitive functioning in continuous flow devices demonstrated that compared with baseline preimplantation continuous flow MCS recipients had improved memory and no cognitive decline through 16 months postimplantation [23] . Their psychological and quality of life status also remained stable preimplantation to postimplantation, although quality of life was reduced [23] .
Liver transplant candidates may experience cognitive impairment due to hepatic encephalopathy, a typically fluctuating cluster of neuropsychiatric and behavioral symptoms that are potentially reversible following transplantation. Overt encephalopathy is easier to identify on clinical exam, but because minimal hepatic encephalopathy (MHE) requires cognitive testing to elicit the symptoms, it often goes undiagnosed and untreated. Nevertheless, MHE can impair functioning and safety (e.g., driving). Although a variety of neurocognitive screening tools can identify MHE, they are often not employed due to lack of clinical time and expertise required for implementation, scoring, and interpretation, especially in the gastroenterology clinics in which liver transplant candidates are commonly managed. One study validated a smartphone application for delivering the Stroop cognitive screening test to detect MHE against a standard battery of neurocognitive tests for MHE [24 && ]. Although the intent of the Stroop screening app is to supplement clinical judgment as point-of-care testing, a self-scoring algorithm and mobile device app potentially allows prospective monitoring even from home.
Although organ dysfunction-related cognitive impairment may be reversed by transplantation, other central nervous systems insults may arise after transplant (e.g., postoperative delirium, neuropsychiatric side-effects of immunosuppressants). In a prospective study of cognitive impairment in lung transplant patients, while 45% were impaired pretransplant, 57% showed neurocognitive impairment at discharge from the transplant hospitalization [25] . Although early new-onset neurocognitive impairment associated with delirium tended to improve at follow-up 3 months later, 80% of those who were impaired pretransplant remained impaired at followup. However, on repeat testing, cognitive impairments tended to improve over the months following transplant. Older age and lower education were associated with poorer neurocognitive performance across time points [25] . Similar findings are reported in a cross-sectional study of lung recipients showing 67% had mild cognitive impairment [26] . In a cohort of liver transplant patients, features of cognitive impairment characteristic of hepatic encephalopathy largely resolved after transplant [27] . New-onset cognitive impairments emerged by 1-year posttransplant in 70% of recipients and were not related to a history of encephalopathy or prior alcohol use. The cognitive decline continued up until 12 months after transplant, suggesting the actual surgery was not the main trigger. Cognitive impairments were also associated with poorer quality of life [27] .
ADHERENCE TO THE AFTER TRANSPLANT REGIMEN
Lifelong adherence to the posttransplant regimen is difficult given the complexity of the regimen. Generally, it involves taking multiple medications on a precise schedule and self-monitoring and reporting on physical signs and symptoms. Unfortunately despite these requirements nonadherence is not uncommon, tends to increase over time, and leads to poorer outcomes [28] . Although pretransplant evaluations can identify individuals who may require assistance with adherence, pretransplant predictors of posttransplant adherence have been difficult to identify [28] .
Due to extent and critical nature of nonadherence the bulk of recent research in transplant psychiatry addresses efforts to understand and prevent it (see Table 1 ) [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] 39 && ,40 & ,41,42 && ]. The kidney transplant literature has shown that mood and perception of self-efficacy are associated with adherence [43] . Other recent work has emphasized the need for patient involvement in selection of treatment. Much of this work is through observational studies and there is a need for randomized control trials to thoroughly test the efficacy of adherence methods and tools. Many of the studies do, however, highlight the importance of increasing patient education and allowing them, with support, to make decisions regarding their care [44] . Technological developments have facilitated patient selfmonitoring of diseases such as diabetes and depression. In organ transplantation, technology-based interventions hold promise for improving patient self-monitoring and adherence to posttransplant care, ideally increasing patients' involvement in their care.
LIVING DONOR ISSUES
Living donors make a personal sacrifice by undergoing surgery to provide a part or whole organ to enhance the welfare of another. Their safety and wellbeing are priorities in organ transplantation. Most studies examine donor outcomes to identify the types and predictors of poorer outcomes with the intent to educate clinicians who perform the psychosocial evaluations and inform future interventions. The study by Chen et al. [45] of living lung donors found that, although donation was well tolerated with no limitations in daily activity and preserved pulmonary function, donors experienced increased dyspnea, decreased health-related quality of life, and, in donors whose recipients died, decreased sleep quality. A separate study by the same group showed that living donor parents who donated a kidney to their adult child suffered more depression and anxiety and had worse physical functioning than living sibling donors [46] . A study of quality of life among living donors showed that although the incidence of depression and anxiety among living donors postdonation is comparable to that of age-matched and sex-matched peers, increased stressors, more complicated recovery, and ambivalence to donation increase the risk of these conditions [47] . Several studies conclude that many donors do not retain enough information about the procedure to make an informed decision to donate, that computer-based education can alert transplant teams to potential donors who lack sufficient understanding to give informed consent, and that home-based education of donors and recipients can increase willingness to be a living donor [48] [49] [50] . Because ambivalence has been associated with poorer outcomes after donation Dew et al. [51 & ] conducted a predonation randomized controlled intervention trial using motivational interviewing to address residual ambivalence among donors. The motivational interviewing intervention reduced predonation ambivalence and following donation those in the intervention reported fewer perceived physical symptoms, less pain and fatigue postdonation, and a lower incidence of anxiety but not depression.
CONCLUSION
These recent studies reflect a willingness of transplant programmes to consider candidates with complex mental health and addiction histories. Although psychiatrists and mental health providers are benefitted by the available observational studies that identify psychosocial-risk factors for poorer mental health and transplant outcomes, interventions targeting known risk factors are lacking. Pretransplant studies are uncommon but could address issues with early identification of problems and preparation for transplantation. This timeframe is critical to addressing substance use disorders. Preserving the wellbeing of living organ donors requires greater attention to consenting and preparation prior to the donation surgery. Following transplant careful attention to mood disorders and cognitive limitations is needed. Cognitive impairment can worsen in the immediate aftermath of transplantation and may improve over time but may not normalize and sometimes may be worse than baseline. Strategies to empower recipients to manage their new organ, particularly in tandem with the help of multidisciplinary transplant teams are needed. These studies need to address more than just one aspect of adherence and need to consider the problem of increasing nonadherence over time.
